Skip to main content
PMC home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2010 Oct 8;11(6):457–468. doi: 10.1007/s10194-010-0257-5

Are the current IHS guidelines for migraine drug trials being followed?

Anders Hougaard 1, Peer Tfelt-Hansen 1,✉
PMCID: PMC3476229  PMID: 20931348

Abstract

In 2000, the Clinical Trials Subcommittee of the International Headache Society (IHS) published the second edition of its guidelines for controlled trials of drugs in migraine. The purpose of this publication was to improve the quality of such trials by increasing the awareness amongst investigators of the methodological issues specific to this particular illness. Until now the adherence to these guidelines has not been systematically assessed. We reviewed all published controlled trials of drugs in migraine from 2002 to 2008. Eligible trials were scored for compliance with the IHS guidelines by using grading scales based on the most essential recommendations of the guidelines. The primary efficacy measure of each trial was also recorded. A total of 145 trials of acute treatment and 52 trials of prophylactic treatment were eligible for review. Of the randomized, double-blind trials, acute trials scored an average of 4.7 out of 7 while prophylactic trials scored an average of 5.6 out of 9 for compliance. Thirty-one percent of acute trials and 72% of prophylactic trials used the recommended primary efficacy measure. Fourteen percent of the reviewed trials were either not randomized or not double-blinded. Adherence to international guidelines like these of IHS is important to ensure that only high-quality trials are performed, and to provide the consensus that is required for meta analyses. The primary efficacy measure for trials of acute treatment should be “pain free” and not “headache relief”. Open-label or non-randomized trials generally have no place in the study of migraine drugs.

Keywords: Migraine, Randomised clinical trials, Acute treatment, Prophylactic treatment, Efficacy parameters

Full Text

The Full Text of this article is available as a PDF (282.8 KB).

Conflict of interest

None.

References

  • 1.Tfelt-Hansen P, Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259–1287. doi: 10.2165/00003495-200060060-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Lampl C, Voelker M, Diener HC. Efficacy and safety of 1, 000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254:705–712. doi: 10.1007/s00415-007-0547-2. [DOI] [PubMed] [Google Scholar]
  • 3.Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668–1675. doi: 10.1016/S0140-6736(01)06711-3. [DOI] [PubMed] [Google Scholar]
  • 4.Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr.Opin.Neurol. 2008;21:331–337. doi: 10.1097/WCO.0b013e3282fee843. [DOI] [PubMed] [Google Scholar]
  • 5.Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine : what are the implications? CNS Drugs. 2007;21:877–883. doi: 10.2165/00023210-200721110-00001. [DOI] [PubMed] [Google Scholar]
  • 6.Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study. Eur J Epidemiol. 2005;20:1007–1014. doi: 10.1007/s10654-005-3778-5. [DOI] [PubMed] [Google Scholar]
  • 7.Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KM (2006) The headaches, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
  • 8.Villalon CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009;124:309–323. doi: 10.1016/j.pharmthera.2009.09.003. [DOI] [PubMed] [Google Scholar]
  • 9.Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet. 1997;349:401–402. doi: 10.1016/S0140-6736(97)80021-9. [DOI] [PubMed] [Google Scholar]
  • 10.Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia. 2009;29:742–750. doi: 10.1111/j.1468-2982.2008.01804.x. [DOI] [PubMed] [Google Scholar]
  • 11.Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 2009;8:718–723. doi: 10.1016/S1474-4422(09)70135-8. [DOI] [PubMed] [Google Scholar]
  • 12.Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. Lancet. 2009;374:1501–1502. doi: 10.1016/S0140-6736(09)61906-1. [DOI] [PubMed] [Google Scholar]
  • 13.(1991) Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia 11:1–12 [PubMed]
  • 14.Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765–786. doi: 10.1046/j.1468-2982.2000.00117.x. [DOI] [PubMed] [Google Scholar]
  • 15.European Medicines Agency (2007) Guideline on Clinical Investigation of Medicinal Products for the Treatment of Migraine. European Medicines Agency, London
  • 16.The Cochrane Collaboration (2009) The Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. The Cochrane Collaboration, Oxford
  • 17.Alemdar M, Pekdemir M, Selekler HM. Single-dose intravenous tramadol for acute migraine pain in adults: a single-blind, prospective, randomized, placebo-controlled clinical trial. Clin Ther. 2007;29:1441–1447. doi: 10.1016/j.clinthera.2007.07.017. [DOI] [PubMed] [Google Scholar]
  • 18.Bell CF, Foley KA, Barlas S, Solomon G, Hu XH. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study. Clin Ther. 2006;28:872–880. doi: 10.1016/j.clinthera.2006.06.006. [DOI] [PubMed] [Google Scholar]
  • 19.Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48:1286–1293. doi: 10.1111/j.1526-4610.2008.01092.x. [DOI] [PubMed] [Google Scholar]
  • 20.Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23:141–148. doi: 10.1016/S0736-4679(02)00502-4. [DOI] [PubMed] [Google Scholar]
  • 21.Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo-controlled study. Headache. 2002;42:862–871. doi: 10.1046/j.1526-4610.2002.02204.x. [DOI] [PubMed] [Google Scholar]
  • 22.Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22:345–353. doi: 10.1046/j.1468-2982.2002.00364.x. [DOI] [PubMed] [Google Scholar]
  • 23.Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25:735–742. doi: 10.1111/j.1468-2982.2005.00981.x. [DOI] [PubMed] [Google Scholar]
  • 24.Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297:1443–1454. doi: 10.1001/jama.297.13.1443. [DOI] [PubMed] [Google Scholar]
  • 25.Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20:1465–1472. doi: 10.1185/030079904X2745. [DOI] [PubMed] [Google Scholar]
  • 26.Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006;46:914–924. doi: 10.1111/j.1526-4610.2006.00466.x. [DOI] [PubMed] [Google Scholar]
  • 27.Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004;26:214–223. doi: 10.1016/S0149-2918(04)90020-3. [DOI] [PubMed] [Google Scholar]
  • 28.Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate versus metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005;25:199–204. doi: 10.1111/j.1468-2982.2004.00840.x. [DOI] [PubMed] [Google Scholar]
  • 29.Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17:653–667. doi: 10.2165/00023210-200317090-00005. [DOI] [PubMed] [Google Scholar]
  • 30.Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol. 2003;49:20–29. doi: 10.1159/000067018. [DOI] [PubMed] [Google Scholar]
  • 31.Di Monda V, Nicolodi M, Aloisio A, Del Bianco P, Fonzari M, Grazioli I, Uslenghi C, Vecchiet L, Sicuteri F. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache. 2003;43:835–844. doi: 10.1046/j.1526-4610.2003.03161.x. [DOI] [PubMed] [Google Scholar]
  • 32.Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology. 2002;58:1660–1665. doi: 10.1212/wnl.58.11.1660. [DOI] [PubMed] [Google Scholar]
  • 33.Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol. 2002;47:99–107. doi: 10.1159/000047960. [DOI] [PubMed] [Google Scholar]
  • 34.Diener HC. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia. 2003;23:183–185. doi: 10.1046/j.1468-2982.2003.00496.x. [DOI] [PubMed] [Google Scholar]
  • 35.Diener HC, Bussone G, Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Gobel H, Hartung E, Jimenez MD, Lange R, Manzoni GC, Mueller-Schwefe G, Nappi G, Pinessi L, Prat J, Puca FM, Titus F, Voelker M. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:947–954. doi: 10.1111/j.1468-2982.2004.00783.x. [DOI] [PubMed] [Google Scholar]
  • 36.Diener HC, Eikermann A, Gessner U, Gobel H, Haag G, Lange R, May A, Muller-Schwefe G, Voelker M. Efficacy of 1, 000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol. 2004;52:50–56. doi: 10.1159/000079544. [DOI] [PubMed] [Google Scholar]
  • 37.Diener HC. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. Curr Med Res Opin. 2005;21:1603–1610. doi: 10.1185/030079905X65448. [DOI] [PubMed] [Google Scholar]
  • 38.Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache. 2005;45:874–882. doi: 10.1111/j.1526-4610.2005.05151.x. [DOI] [PubMed] [Google Scholar]
  • 39.Diener HC, Montagna P, Gacs G, Lyczak P, Schumann G, Zoller B, Mulder LJ, Siegel J, Edson K. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537–547. doi: 10.1111/j.1468-2982.2005.01064.x. [DOI] [PubMed] [Google Scholar]
  • 40.Diez FI, Straube A, Zanchin G. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol. 2007;254:242–249. doi: 10.1007/s00415-006-0352-3. [DOI] [PubMed] [Google Scholar]
  • 41.Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs. 2005;19:125–136. doi: 10.2165/00023210-200519020-00003. [DOI] [PubMed] [Google Scholar]
  • 42.Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache. 2002;42:21–27. doi: 10.1046/j.1526-4610.2002.02009.x. [DOI] [PubMed] [Google Scholar]
  • 43.Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22:453–461. doi: 10.1046/j.1468-2982.2002.00394.x. [DOI] [PubMed] [Google Scholar]
  • 44.Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia. 2002;22:101–106. doi: 10.1046/j.1468-2982.2002.00319.x. [DOI] [PubMed] [Google Scholar]
  • 45.Dowson AJ, Charlesworth BR, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs. 2003;17:839–851. doi: 10.2165/00023210-200317110-00005. [DOI] [PubMed] [Google Scholar]
  • 46.Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain. 2005;6:81–87. doi: 10.1007/s10194-005-0156-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Eletriptan Steering Committee in Japan Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia. 2002;22:416–423. doi: 10.1046/j.1468-2982.2002.00372.x. [DOI] [PubMed] [Google Scholar]
  • 48.Engindeniz Z, Demircan C, Karli N, Armagan E, Bulut M, Aydin T, Zarifoglu M. Intramuscular tramadol versus diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. J Headache Pain. 2005;6:143–148. doi: 10.1007/s10194-005-0169-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Farkkila M, Olesen J, Dahlof C, Stovner LJ, ter Bruggen JP, Rasmussen S, Muirhead N, Sikes C. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003;23:463–471. doi: 10.1046/j.1468-2982.2003.00554.x. [DOI] [PubMed] [Google Scholar]
  • 50.Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen versus rizatriptan or acetaminophen alone for acute migraine treatment. Headache. 2008;48:921–930. doi: 10.1111/j.1526-4610.2007.01053.x. [DOI] [PubMed] [Google Scholar]
  • 51.Freitag F, Taylor FR, Hamid MA, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study. Headache. 2008;48:368–377. doi: 10.1111/j.1526-4610.2007.00954.x. [DOI] [PubMed] [Google Scholar]
  • 52.Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, Finlayson G, Wright P, Biondi D. Effect of early intervention with almotriptan versus placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache. 2008;48:341–354. doi: 10.1111/j.1526-4610.2007.01044.x. [DOI] [PubMed] [Google Scholar]
  • 53.Freitag FG, Finlayson G, Rapoport AM, Elkind AH, Diamond ML, Unger JR, Fisher AC, Armstrong RB, Hulihan JF, Greenberg SJ. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS) Headache. 2007;47:519–530. doi: 10.1111/j.1526-4610.2007.00756.x. [DOI] [PubMed] [Google Scholar]
  • 54.Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C, Gallagher EJ. A trial of metoclopramide versus sumatriptan for the emergency department treatment of migraines. Neurology. 2005;64:463–468. doi: 10.1212/01.WNL.0000150904.28131.DD. [DOI] [PubMed] [Google Scholar]
  • 55.Friedman BW, Hochberg M, Esses D, Bijur PE, Corbo J, Paternoster J, Solorzano C, Toosi B, Lipton RB, Gallagher EJ. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache. 2006;46:934–941. doi: 10.1111/j.1526-4610.2006.00467.x. [DOI] [PubMed] [Google Scholar]
  • 56.Friedman BW, Greenwald P, Bania TC, Esses D, Hochberg M, Solorzano C, Corbo J, Chu J, Chew E, Cheung P, Fearon S, Paternoster J, Baccellieri A, Clark S, Bijur PE, Lipton RB, Gallagher EJ. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69:2038–2044. doi: 10.1212/01.WNL.0000281105.78936.1d. [DOI] [PubMed] [Google Scholar]
  • 57.Friedman BW, Esses D, Solorzano C, Dua N, Greenwald P, Radulescu R, Chang E, Hochberg M, Campbell C, Aghera A, Valentin T, Paternoster J, Bijur P, Lipton RB, Gallagher EJ. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008;52:399–406. doi: 10.1016/j.annemergmed.2007.09.027. [DOI] [PubMed] [Google Scholar]
  • 58.Garcia-Ramos G, MacGregor EA, Hilliard B, Bordini CA, Leston J, Hettiarachchi J. Comparative efficacy of eletriptan versus naratriptan in the acute treatment of migraine. Cephalalgia. 2003;23:869–876. doi: 10.1046/j.1468-2982.2003.00593.x. [DOI] [PubMed] [Google Scholar]
  • 59.Gawel M, Aschoff J, May A, Charlesworth BR. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine—results from phase 1 of the REALIZE Study. Headache. 2005;45:7–16. doi: 10.1111/j.1526-4610.2005.05004.x. [DOI] [PubMed] [Google Scholar]
  • 60.Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol. 2002;47:88–98. doi: 10.1159/000047959. [DOI] [PubMed] [Google Scholar]
  • 61.Goadsby PJ, Massiou H, Pascual J, Diener HC, Dahlof CG, Mateos V, Dowson AJ, Raets I, Cunha L, Farkkila M, Manzoni GC. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand. 2007;115:34–40. doi: 10.1111/j.1600-0404.2006.00739.x. [DOI] [PubMed] [Google Scholar]
  • 62.Goadsby PJ, Zanchin G, Geraud G, Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J. Early versus non-early intervention in acute migraine-’Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28:383–391. doi: 10.1111/j.1468-2982.2008.01546.x. [DOI] [PubMed] [Google Scholar]
  • 63.Gobel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebo-controlled, randomized study. Cephalalgia. 2004;24:888–893. doi: 10.1111/j.1468-2982.2004.00764.x. [DOI] [PubMed] [Google Scholar]
  • 64.Goldstein J, Keywood C. Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache. 2002;42:41–48. doi: 10.1046/j.1526-4610.2002.02012.x. [DOI] [PubMed] [Google Scholar]
  • 65.Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, Battikha JP, Hoffman H, Baggish J. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache. 2005;45:973–982. doi: 10.1111/j.1526-4610.2005.05177.x. [DOI] [PubMed] [Google Scholar]
  • 66.Goldstein J, Silberstein SD, Saper JR, Ryan RE, Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache. 2006;46:444–453. doi: 10.1111/j.1526-4610.2006.00376.x. [DOI] [PubMed] [Google Scholar]
  • 67.Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123. doi: 10.1016/S0140-6736(08)61626-8. [DOI] [PubMed] [Google Scholar]
  • 68.Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–1312. doi: 10.1212/01.WNL.0000286940.29755.61. [DOI] [PubMed] [Google Scholar]
  • 69.Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006;46:781–787. doi: 10.1111/j.1526-4610.2006.00438.x. [DOI] [PubMed] [Google Scholar]
  • 70.Ishkanian G, Blumenthal H, Webster CJ, Richardson MS, Ames M. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:99–109. doi: 10.1016/j.clinthera.2007.01.012. [DOI] [PubMed] [Google Scholar]
  • 71.Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45:850–861. doi: 10.1111/j.1526-4610.2005.05153.x. [DOI] [PubMed] [Google Scholar]
  • 72.Jamieson D, Cutrer FM, Goldstein J, Dayno J, Hu XH. Real-world experiences in migraine therapy with rizatriptan. Headache. 2003;43:223–230. doi: 10.1046/j.1526-4610.2003.03045.x. [DOI] [PubMed] [Google Scholar]
  • 73.Jelinski SE, Becker WJ, Christie SN, Ahmad FE, Pryse-Phillips W, Simpson SD. Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci. 2006;33:73–79. doi: 10.1017/s031716710000473x. [DOI] [PubMed] [Google Scholar]
  • 74.Kaniecki R, Ruoff G, Smith T, Barrett PS, Ames MH, Byrd S, Kori S. Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache. Curr Med Res Opin. 2006;22:1535–1544. doi: 10.1185/030079906X115685. [DOI] [PubMed] [Google Scholar]
  • 75.Kelly AM, Kerr D, Clooney M. Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial. Emerg Med J. 2008;25:26–29. doi: 10.1136/emj.2007.052068. [DOI] [PubMed] [Google Scholar]
  • 76.Klapper J, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004;24:918–924. doi: 10.1111/j.1468-2982.2004.00735.x. [DOI] [PubMed] [Google Scholar]
  • 77.Kolodny A, Polis A, Battisti WP, Johnson-Pratt L, Skobieranda F. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia. 2004;24:540–546. doi: 10.1111/j.1468-2982.2004.00707.x. [DOI] [PubMed] [Google Scholar]
  • 78.Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib versus rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia. 2002;22:309–312. doi: 10.1046/j.1468-2982.2002.00369.x. [DOI] [PubMed] [Google Scholar]
  • 79.Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 2004;4:10. doi: 10.1186/1471-2377-4-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Krymchantowski AV, Peixoto P, Higashi R, Silva A, Jr, Schutz V. Lysine clonixinate vs naproxen sodium for the acute treatment of migraine: a double-blind, randomized, crossover study. Med Gen Med. 2005;7:69. [PMC free article] [PubMed] [Google Scholar]
  • 81.Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan versus rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia. 2006;26:871–874. doi: 10.1111/j.1468-2982.2006.01136.x. [DOI] [PubMed] [Google Scholar]
  • 82.Krymchantowski AV, Carneiro H, Barbosa J, Jevoux C. Lysine clonixinate versus dipyrone (metamizole) for the acute treatment of severe migraine attacks: a single-blind, randomized study. Arq Neuropsiquiatr. 2008;66:216–220. doi: 10.1590/s0004-282x2008000200015. [DOI] [PubMed] [Google Scholar]
  • 83.Kudrow D, Thomas HM, Ruoff G, Ishkanian G, Sands G, Le VH, Brown MT. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. Headache. 2005;45:1151–1162. doi: 10.1111/j.1526-4610.2005.00238.x. [DOI] [PubMed] [Google Scholar]
  • 84.Lainez MJ, Evers S, Kinge E, Allais G, Allen C, Rao NA, Massaad R, Lis K. Preference for rizatriptan 10-mg wafer versus eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia. 2006;26:246–256. doi: 10.1111/j.1468-2982.2006.00991.x. [DOI] [PubMed] [Google Scholar]
  • 85.Lainez MJ, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol. 2007;14:269–275. doi: 10.1111/j.1468-1331.2006.01594.x. [DOI] [PubMed] [Google Scholar]
  • 86.Lampl C, Huber G, Haas S, Rittberger E, Diener HC. Difference in triptan effect in patients with migraine and early allodynia. Cephalalgia. 2008;28:1031–1038. doi: 10.1111/j.1468-2982.2008.01642.x. [DOI] [PubMed] [Google Scholar]
  • 87.Landy S, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract. 2004;58:913–919. doi: 10.1111/j.1368-5031.2004.00295.x. [DOI] [PubMed] [Google Scholar]
  • 88.Landy SH, McGinnis JE, McDonald SA. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan. Headache. 2005;45:346–349. doi: 10.1111/j.1526-4610.2005.05072.x. [DOI] [PubMed] [Google Scholar]
  • 89.Leinisch E, Evers S, Kaempfe N, Kraemer C, Sostak P, Jurgens T, Straube A, May A. Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: a double-blind, placebo-controlled parallel group multicenter study. Pain. 2005;117:396–400. doi: 10.1016/j.pain.2005.07.002. [DOI] [PubMed] [Google Scholar]
  • 90.Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005;45:42–46. doi: 10.1111/j.1526-4610.2005.05009.x. [DOI] [PubMed] [Google Scholar]
  • 91.Levy MJ, Matharu MS, Bhola R, Meeran K, Goadsby PJ. Octreotide is not effective in the acute treatment of migraine. Cephalalgia. 2005;25:48–55. doi: 10.1111/j.1468-2982.2004.00807.x. [DOI] [PubMed] [Google Scholar]
  • 92.Linde M, Mellberg A, Dahlof C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia. 2006;26:113–121. doi: 10.1111/j.1468-2982.2005.00999.x. [DOI] [PubMed] [Google Scholar]
  • 93.Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 2008;48:1326–1336. doi: 10.1111/j.1526-4610.2008.01138.x. [DOI] [PubMed] [Google Scholar]
  • 94.Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for the treatment of acute migraine. Headache. 2005;45:283–292. doi: 10.1111/j.1526-4610.2005.05065.x. [DOI] [PubMed] [Google Scholar]
  • 95.Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004;44:120–130. doi: 10.1111/j.1526-4610.2004.04027.x. [DOI] [PubMed] [Google Scholar]
  • 96.Loder E, Freitag FG, Adelman J, Pearlmand S, Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Curr Med Res Opin. 2005;21:381–389. doi: 10.1185/030079905X28926. [DOI] [PubMed] [Google Scholar]
  • 97.Loo CY, Tan HJ, Teh HS, Raymond AA. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J. 2007;48:834–839. [PubMed] [Google Scholar]
  • 98.MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache. 2002;42:249–255. doi: 10.1046/j.1526-4610.2002.02076.x. [DOI] [PubMed] [Google Scholar]
  • 99.Mannix LK, Loder E, Nett R, Mueller L, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27:414–421. doi: 10.1111/j.1468-2982.2007.01313.x. [DOI] [PubMed] [Google Scholar]
  • 100.Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005;12:774–781. doi: 10.1111/j.1468-1331.2005.01076.x. [DOI] [PubMed] [Google Scholar]
  • 101.Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache. 2003;43:214–222. doi: 10.1046/j.1526-4610.2003.03044.x. [DOI] [PubMed] [Google Scholar]
  • 102.Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache. 2004;44:669–673. doi: 10.1111/j.1526-4610.2004.04125.x. [DOI] [PubMed] [Google Scholar]
  • 103.Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study) Headache. 2007;47:189–198. doi: 10.1111/j.1526-4610.2006.00686.x. [DOI] [PubMed] [Google Scholar]
  • 104.Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21:173–175. doi: 10.1016/S0735-6757(02)42256-5. [DOI] [PubMed] [Google Scholar]
  • 105.Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J. 2004;80:720–723. doi: 10.1136/pgmj.2003.012393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J Headache Pain. 2007;8:175–179. doi: 10.1007/s10194-007-0386-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003;102:835–842. doi: 10.1016/S0029-7844(03)00659-8. [DOI] [PubMed] [Google Scholar]
  • 108.Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11:671–677. doi: 10.1111/j.1468-1331.2004.00914.x. [DOI] [PubMed] [Google Scholar]
  • 109.Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104–1110. doi: 10.1056/NEJMoa030505. [DOI] [PubMed] [Google Scholar]
  • 110.Peroutka SJ, Lyon JA, Swarbrick J, Lipton RB, Kolodner K, Goldstein J. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. Headache. 2004;44:136–141. doi: 10.1111/j.1526-4610.2004.04029.x. [DOI] [PubMed] [Google Scholar]
  • 111.Rapoport A, Ryan R, Goldstein J, Keywood C. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache. 2002;42(Suppl 2):S74–S83. doi: 10.1046/j.1526-4610.42.s2.5.x. [DOI] [PubMed] [Google Scholar]
  • 112.Richman PB, Allegra J, Eskin B, Doran J, Reischel U, Kaiafas C, Nashed AH. A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. Am J Emerg Med. 2002;20:39–42. doi: 10.1053/ajem.2002.30007. [DOI] [PubMed] [Google Scholar]
  • 113.Rowe BH, Colman I, Edmonds ML, Blitz S, Walker A, Wiens S. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache. 2008;48:333–340. doi: 10.1111/j.1526-4610.2007.00959.x. [DOI] [PubMed] [Google Scholar]
  • 114.Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42(Suppl 2):S84–S92. doi: 10.1046/j.1526-4610.42.s2.6.x. [DOI] [PubMed] [Google Scholar]
  • 115.Sakai F, Iwata M, Tashiro K, Itoyama Y, Tsuji S, Fukuuchi Y, Sobue G, Nakashima K, Morimatsu M. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study. Cephalalgia. 2002;22:376–383. doi: 10.1046/j.1468-2982.2002.00377.x. [DOI] [PubMed] [Google Scholar]
  • 116.Sandrini G, Farkkila M, Burgess G, Forster E, Haughie S. Eletriptan versus sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology. 2002;59:1210–1217. doi: 10.1212/wnl.59.8.1210. [DOI] [PubMed] [Google Scholar]
  • 117.Sandrini G, Cerbo R, Del Bene E, Ferrari A, Genco S, Grazioli I, Martelletti P, Nappi G, Pinessi L, Sarchielli P, Tamburro P, Uslenghi C, Zanchin G. Efficacy of double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract. 2007;61:1256–1269. doi: 10.1111/j.1742-1241.2007.01458.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia. 2004;24:596–602. doi: 10.1111/j.1468-2982.2004.00723.x. [DOI] [PubMed] [Google Scholar]
  • 119.Saper J, Dahlof C, So Y, Tfelt-Hansen P, Malbecq W, Loeys T, Barraclough E, Klipfel M, Lines C, Visser H, Reines S, Yuen E. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache. 2006;46:264–275. doi: 10.1111/j.1526-4610.2006.00334.x. [DOI] [PubMed] [Google Scholar]
  • 120.Schoenen J, Pascual J, Rasmussen S, Sun W, Sikes C, Hettiarachchi J. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur J Neurol. 2005;12:108–117. doi: 10.1111/j.1468-1331.2004.00893.x. [DOI] [PubMed] [Google Scholar]
  • 121.Schoenen J, De KlippelN, Giurgea S, Herroelen L, Jacquy J, Louis P, Monseu G, Vandenheede M. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia. 2008;28:1095–1105. doi: 10.1111/j.1468-2982.2008.01654.x. [DOI] [PubMed] [Google Scholar]
  • 122.Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004;24:925–933. doi: 10.1111/j.1468-2982.2004.00802.x. [DOI] [PubMed] [Google Scholar]
  • 123.Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-non-responsive migraineurs. Headache. 2003;43:729–733. doi: 10.1046/j.1526-4610.2003.03130.x. [DOI] [PubMed] [Google Scholar]
  • 124.Sharma S, Prasad A, Nehru R, Anand KS, Rishi RK, Chaturvedi S, Bapna JS, Sharma DR. Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. Headache. 2002;42:896–902. doi: 10.1046/j.1526-4610.2002.02210.x. [DOI] [PubMed] [Google Scholar]
  • 125.Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache. 2003;43:202–213. doi: 10.1046/j.1526-4610.2003.03043.x. [DOI] [PubMed] [Google Scholar]
  • 126.Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther. 2005;27:407–417. doi: 10.1016/j.clinthera.2005.04.003. [DOI] [PubMed] [Google Scholar]
  • 127.Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P, Venkatraman S, Vrijens F, Malbecq W, Lines C, Visser WH, Reines S, Yuen E. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology. 2004;62:1552–1557. doi: 10.1212/01.wnl.0000123260.61631.c4. [DOI] [PubMed] [Google Scholar]
  • 128.Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology. 2003;60:315–321. doi: 10.1212/01.wnl.0000042477.63516.b2. [DOI] [PubMed] [Google Scholar]
  • 129.Silberstein SD, Freitag FG, Rozen TD, Kudrow DB, Hewitt DJ, Jordan DM, Fisher AC, Rosenthal NR. Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache. 2005;45:1317–1327. doi: 10.1111/j.1526-4610.2005.00264.x. [DOI] [PubMed] [Google Scholar]
  • 130.Silberstein SD, Mannix LK, Goldstein J, Couch JR, Byrd SC, Ames MH, McDonald SA, Lener SE, Toso C. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71:114–121. doi: 10.1212/01.wnl.0000316800.22949.20. [DOI] [PubMed] [Google Scholar]
  • 131.Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983–991. doi: 10.1111/j.1526-4610.2005.05178.x. [DOI] [PubMed] [Google Scholar]
  • 132.Spierings EL, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs. 2004;18:1133–1141. doi: 10.2165/00023210-200418150-00007. [DOI] [PubMed] [Google Scholar]
  • 133.Stark R, Dahlof C, Haughie S, Hettiarachchi J. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia. 2002;22:23–32. doi: 10.1046/j.1468-2982.2002.00300.x. [DOI] [PubMed] [Google Scholar]
  • 134.Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia. 2003;23:942–952. doi: 10.1046/j.1468-2982.2003.00617.x. [DOI] [PubMed] [Google Scholar]
  • 135.Stronks DL, Tulen JH, Bussmann HB, Mulder LJ, Passchier J. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. Headache. 2003;43:845–852. doi: 10.1046/j.1526-4610.2003.03162.x. [DOI] [PubMed] [Google Scholar]
  • 136.Sunshine A, Mulhern SA, Olson N, Elkind A, Almas M, Sikes C. Comparative sensitivity of stopwatch methodology and conventional pain assessment measures for detecting early response to triptans in migraine: results of a randomized, open-label pilot study. Clin Ther. 2006;28:1107–1115. doi: 10.1016/j.clinthera.2006.08.010. [DOI] [PubMed] [Google Scholar]
  • 137.Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003;41:847–853. doi: 10.1067/mem.2003.195. [DOI] [PubMed] [Google Scholar]
  • 138.Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, Kuhn TA. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Headache. 2006;46:115–124. doi: 10.1111/j.1526-4610.2006.00300.x. [DOI] [PubMed] [Google Scholar]
  • 139.Tfelt-Hansen P, Bach FW, Daugaard D, Tsiropoulos I, Riddersholm B. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study. J Headache Pain. 2006;7:389–394. doi: 10.1007/s10194-006-0333-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140.Tietjen GE, Athanas K, Utley C, Herial NA, Khuder SA. The combination of naratriptan and prochlorperazine in migraine treatment. Headache. 2005;45:751–753. doi: 10.1111/j.1526-4610.2005.05143_1.x. [DOI] [PubMed] [Google Scholar]
  • 141.Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20:1019–1026. doi: 10.2165/00023210-200620120-00005. [DOI] [PubMed] [Google Scholar]
  • 142.Vecsei L, Gallacchi G, Sagi I, Semjen J, Tajti J, Szok D, Muller M, Vadass P, Kerekgyarto M. Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study. Cephalalgia. 2007;27:29–34. doi: 10.1111/j.1468-2982.2007.01236.x. [DOI] [PubMed] [Google Scholar]
  • 143.Vollono C, Capuano A, Mei D, Ferraro D, Pierguidi L, Evangelista M, Di TrapaniG. Multiple attack study on the available triptans in Italy versus placebo. Eur J Neurol. 2005;12:557–563. doi: 10.1111/j.1468-1331.2005.01030.x. [DOI] [PubMed] [Google Scholar]
  • 144.Wang SJ, Fuh JL, Wu ZA. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc. 2007;70:39–46. doi: 10.1016/S1726-4901(09)70300-4. [DOI] [PubMed] [Google Scholar]
  • 145.Wendt J, Cady R, Singer R, Peters K, Webster C, Kori S, Byrd S. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006;28:517–526. doi: 10.1016/j.clinthera.2006.03.013. [DOI] [PubMed] [Google Scholar]
  • 146.Wentz AL, Jimenez TB, Dixon RM, Aurora SK, Gold M. A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine. Eur J Neurol. 2008;15:420–427. doi: 10.1111/j.1468-1331.2008.02093.x. [DOI] [PubMed] [Google Scholar]
  • 147.Winner P, Mannix LK, Putnam DG, McNeal S, Kwong J, O’Quinn S, Richardson MS. Pain-free results with sumatriptan taken at the first sign of migraine pain: two randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003;78:1214–1222. doi: 10.4065/78.10.1214. [DOI] [PubMed] [Google Scholar]
  • 148.Winner P, Adelman J, Aurora S, Lener ME, Ames M. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults. Clin Ther. 2006;28:1582–1591. doi: 10.1016/j.clinthera.2006.10.011. [DOI] [PubMed] [Google Scholar]
  • 149.Anand KS, Prasad A, Singh MM, Sharma S, Bala K. Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther. 2006;13:183–187. doi: 10.1097/01.mjt.0000212705.79248.74. [DOI] [PubMed] [Google Scholar]
  • 150.Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate versus propranolol in migraine prophylaxis. Acta Neurol Scand. 2008;118:301–305. doi: 10.1111/j.1600-0404.2008.01087.x. [DOI] [PubMed] [Google Scholar]
  • 151.Aurora SK, Gawel M, Brandes JL, Pokta S, VanDenburgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47:486–499. doi: 10.1111/j.1526-4610.2007.00853.x. [DOI] [PubMed] [Google Scholar]
  • 152.Bartolini M, Silvestrini M, Taffi R, Lanciotti C, Luconi R, Capecci M, Provinciali L. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol. 2005;28:277–279. doi: 10.1097/01.wnf.0000192136.46145.44. [DOI] [PubMed] [Google Scholar]
  • 153.Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48:210–220. doi: 10.1111/j.1526-4610.2007.00949.x. [DOI] [PubMed] [Google Scholar]
  • 154.Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–973. doi: 10.1001/jama.291.8.965. [DOI] [PubMed] [Google Scholar]
  • 155.Brandes JL, Visser WH, Farmer MV, Schuhl AL, Malbecq W, Vrijens F, Lines CR, Reines SA. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. Headache. 2004;44:581–586. doi: 10.1111/j.1526-4610.2004.446006.x. [DOI] [PubMed] [Google Scholar]
  • 156.Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:44–48. doi: 10.1016/j.clineuro.2004.03.004. [DOI] [PubMed] [Google Scholar]
  • 157.Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, Beukelaar F. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002;22:209–221. doi: 10.1046/j.1468-2982.2002.t01-1-00309.x. [DOI] [PubMed] [Google Scholar]
  • 158.Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, Neto W, Vijapurkar U, Doyle A, Jacobs D. Topiramate in migraine prophylaxis—results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943–950. doi: 10.1007/s00415-004-0464-6. [DOI] [PubMed] [Google Scholar]
  • 159.Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. 2005;25:1031–1041. doi: 10.1111/j.1468-2982.2005.00950.x. [DOI] [PubMed] [Google Scholar]
  • 160.Diener HC, Bussone G, Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–823. doi: 10.1111/j.1468-2982.2007.01326.x. [DOI] [PubMed] [Google Scholar]
  • 161.Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Del Rio MS, Schoenen J, Schwalen S, Oene J. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007;6:1054–1062. doi: 10.1016/S1474-4422(07)70272-7. [DOI] [PubMed] [Google Scholar]
  • 162.Donaldson D, Sundermann R, Jackson R, Bastani A. Intravenous dexamethasone versus placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med. 2008;26:124–130. doi: 10.1016/j.ajem.2007.03.029. [DOI] [PubMed] [Google Scholar]
  • 163.Elkind AH, O’Carroll P, Blumenfeld A, DeGryse R, Dimitrova R. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006;7:688–696. doi: 10.1016/j.jpain.2006.03.002. [DOI] [PubMed] [Google Scholar]
  • 164.Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:838–843. doi: 10.1111/j.1468-2982.2004.00754.x. [DOI] [PubMed] [Google Scholar]
  • 165.Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652–1659. doi: 10.1212/wnl.58.11.1652. [DOI] [PubMed] [Google Scholar]
  • 166.Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache. 2008;48:201–209. doi: 10.1111/j.1526-4610.2007.00963.x. [DOI] [PubMed] [Google Scholar]
  • 167.Guidotti M, Mauri M, Barrila C, Guidotti F, Belloni C. Frovatriptan versus transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Headache Pain. 2007;8:283–288. doi: 10.1007/s10194-007-0417-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168.Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study) Headache. 2007;47:402–412. doi: 10.1111/j.1526-4610.2006.00599.x. [DOI] [PubMed] [Google Scholar]
  • 169.Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110:979–984. doi: 10.1016/j.clineuro.2008.05.025. [DOI] [PubMed] [Google Scholar]
  • 170.Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240–2244. doi: 10.1212/01.wnl.0000147290.68260.11. [DOI] [PubMed] [Google Scholar]
  • 171.MacGregor EA, Hackshaw A. Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebo-controlled pilot study using natural oestrogen supplements. J Fam Plann Reprod Health Care. 2002;28:27–31. doi: 10.1783/147118902101195974. [DOI] [PubMed] [Google Scholar]
  • 172.MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006;67:2159–2163. doi: 10.1212/01.wnl.0000249114.52802.55. [DOI] [PubMed] [Google Scholar]
  • 173.Magis D, Ambrosini A, Sandor P, Jacquy J, Laloux P, Schoenen J. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache. 2007;47:52–57. doi: 10.1111/j.1526-4610.2006.00626.x. [DOI] [PubMed] [Google Scholar]
  • 174.Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004;44:885–890. doi: 10.1111/j.1526-4610.2004.04170.x. [DOI] [PubMed] [Google Scholar]
  • 175.Mannix LK, Savani N, Landy S, Valade D, Shackelford S, Ames MH, Jones MW. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007;47:1037–1049. doi: 10.1111/j.1526-4610.2007.00855.x. [DOI] [PubMed] [Google Scholar]
  • 176.Mei D, Capuano A, Vollono C, Evangelista M, Ferraro D, Tonali P, Di Trapani G. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci. 2004;25:245–250. doi: 10.1007/s10072-004-0350-0. [DOI] [PubMed] [Google Scholar]
  • 177.Millan-Guerrero RO, Pineda-Lucatero AG, Hernandez-Benjamin T, Tene CE, Pacheco MF. Nalpha-methylhistamine safety and efficacy in migraine prophylaxis: phase I and phase II studies. Headache. 2003;43:389–394. doi: 10.1046/j.1526-4610.2003.03074.x. [DOI] [PubMed] [Google Scholar]
  • 178.Millan-Guerrero RO, Isais-Millan R, Benjamin TH, Tene CE. Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. Can.J Neurol.Sci. 2006;33:195–199. doi: 10.1017/s0317167100004960. [DOI] [PubMed] [Google Scholar]
  • 179.Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Rivera-Castano L, Garcia-Solorzano A, Lopez-Blanca C, Membrila-Maldonado M, Munoz-Solis R. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study. Eur J Neurol. 2007;14:1079–1084. doi: 10.1111/j.1468-1331.2007.01744.x. [DOI] [PubMed] [Google Scholar]
  • 180.Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Gutierrez I, Rivera-Castano L, Trujillo-Hernandez B, Baltazar LM. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol. 2008;59:237–242. doi: 10.1159/000115637. [DOI] [PubMed] [Google Scholar]
  • 181.Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis—a double-blind, multicentre, randomized placebo-controlled dose–response study. Cephalalgia. 2002;22:523–532. doi: 10.1046/j.1468-2982.2002.00396.x. [DOI] [PubMed] [Google Scholar]
  • 182.Pradalier A, Lanteri-Minet M, Geraud G, Allain H, Lucas C, Delgado A. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs. 2004;18:1149–1163. doi: 10.2165/00023210-200418150-00009. [DOI] [PubMed] [Google Scholar]
  • 183.Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007;27:492–503. doi: 10.1111/j.1468-2982.2007.01315.x. [DOI] [PubMed] [Google Scholar]
  • 184.Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64:713–715. doi: 10.1212/01.WNL.0000151975.03598.ED. [DOI] [PubMed] [Google Scholar]
  • 185.Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med. 2007;8:478–485. doi: 10.1111/j.1526-4637.2006.00168.x. [DOI] [PubMed] [Google Scholar]
  • 186.Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Headache. 2008;48:118–125. doi: 10.1111/j.1526-4610.2007.00785.x. [DOI] [PubMed] [Google Scholar]
  • 187.Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46:642–648. doi: 10.1111/j.1526-4610.2006.00413.x. [DOI] [PubMed] [Google Scholar]
  • 188.Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D’Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008;70:548–555. doi: 10.1212/01.wnl.0000297551.27191.70. [DOI] [PubMed] [Google Scholar]
  • 189.Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261–269. doi: 10.1212/01.wnl.0000134620.30129.d6. [DOI] [PubMed] [Google Scholar]
  • 190.Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490–495. doi: 10.1001/archneur.61.4.490. [DOI] [PubMed] [Google Scholar]
  • 191.Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M. Efficacy and tolerability of topiramate 200 mg/day in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28:1002–1011. doi: 10.1016/j.clinthera.2006.07.003. [DOI] [PubMed] [Google Scholar]
  • 192.Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–180. doi: 10.1111/j.1526-4610.2006.00684.x. [DOI] [PubMed] [Google Scholar]
  • 193.Togha M, Rahmat Jirde M, Nilavari K, Ashrafian H, Razeghi S, Kohan L. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. J Headache Pain. 2008;9:77–82. doi: 10.1007/s10194-008-0044-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 194.Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65–69. doi: 10.1001/jama.289.1.65. [DOI] [PubMed] [Google Scholar]
  • 195.Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22:877–886. doi: 10.2165/00023210-200822100-00007. [DOI] [PubMed] [Google Scholar]
  • 196.Vo AH, Satori R, Jabbari B, Green J, Killgore WD, Labutta R, Campbell WW. Botulinum toxin type-A in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med. 2007;78:B113–B118. [PubMed] [Google Scholar]
  • 197.Seggern RL, Mannix LK, Adelman JU. Rofecoxib in the prevention of perimenstrual migraine: an open-label pilot trial. Headache. 2004;44:160–165. doi: 10.1111/j.1526-4610.2004.04033.x. [DOI] [PubMed] [Google Scholar]
  • 198.Wammes-van der Heijden EA, Smidt MH, Tijssen CC, van’t Hoff AR, Lenderink AW, Egberts AC. Effect of low-intensity acenocoumarol on frequency and severity of migraine attacks. Headache. 2005;45:137–143. doi: 10.1111/j.1526-4610.2005.05028.x. [DOI] [PubMed] [Google Scholar]
  • 199.Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol. 1991;31:295–299. doi: 10.1159/000116757. [DOI] [PubMed] [Google Scholar]
  • 200.Prior MJ, Codispoti JR, Fu M. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache. 2010;50:819–833. doi: 10.1111/j.1526-4610.2010.01638.x. [DOI] [PubMed] [Google Scholar]
  • 201.Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000;20:554–560. doi: 10.1046/j.1468-2982.2000.00082.x. [DOI] [PubMed] [Google Scholar]
  • 202.Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39:20–26. doi: 10.1111/j.1526-4610.1999.00006.x. [DOI] [Google Scholar]
  • 203.Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia. 2003;23:487–490. doi: 10.1046/j.1468-2982.2003.00528.x. [DOI] [PubMed] [Google Scholar]
  • 204.Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N, Gebeline-Myers C. Patients’ preference for migraine preventive therapy. Headache. 2007;47:540–545. doi: 10.1111/j.1526-4610.2007.00757.x. [DOI] [PubMed] [Google Scholar]
  • 205.Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6:7–14. doi: 10.1046/j.1468-2982.1986.0601007.x. [DOI] [PubMed] [Google Scholar]
  • 206.Bendtsen L, Bigal ME, Cerbo R, Diener HC, Holroyd K, Lampl C, Mitsikostas DD, Steiner TJ, Tfelt-Hansen P (2009) Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia [DOI] [PubMed]
  • 207.Olesen J, Krabbe AA, Tfelt-Hansen P. Methodological aspects of prophylactic drug trials in migraine. Cephalalgia. 1981;1:127–141. doi: 10.1046/j.1468-2982.1981.0103127.x. [DOI] [PubMed] [Google Scholar]
  • 208.Hauge AW, Hougaard A, Olesen J. On the methodology of drug trials in migraine with aura. Cephalalgia. 2010;30:1041–1048. doi: 10.1177/0333102409359091. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES